The University of Arizona
Professor Hulme has extensive experience of each phase of the drug discovery value chain having had functional responsibility for > 55 individual targets over a 20 year period and built two compound collections spanning both private and public sectors. He obtained his PhD at age 25 under the tutelage of Professor Jack Baldwin at Oxford University. He moved to the University of Arizona in 2007, after holding senior management positions at Sanofi-Aventis (’94-’99), Amgen (’99-2004) and Eli Lilly (2004-2007) establishing and running High-throughput Medicinal Chemistry groups. In 2010, he was the founder of BIO5 Drug Discovery after being the recipient of a $7.5 million grant from the NIH. In 2011, he was named the University of Arizona Innovator of the Year. He has over 185 papers, patents, abstracts and book chapters to his name with current research interests including targets for Alzheimer’s, prostate and colon cancer, and multi-component reaction/methodology development for file enhancement.
His research interest includes targets for Alzheimer’s, prostate and colon cancer, and multi-component reaction/methodology development for file enhancement